Literature DB >> 17391381

Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals.

F M MacKenzie1, J Bruce, M J Struelens, H Goossens, J Mollison, I M Gould.   

Abstract

Major regional variations in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) are observed across Europe. This study investigated hospital MRSA prevalence in relation to patterns of antimicrobial use and infection control policies in an observational, cross-sectional study that used retrospective data from 2001 and linear regression to model relationships. MRSA prevalence (median 20.8%, n = 173 hospitals) and antimicrobial consumption (median 55.2 defined daily doses/100 bed-days, n = 140 hospitals) both varied significantly according to geographical region (p <0.001). MRSA prevalence and antimicrobial consumption data were provided by 128 hospitals, and showed a strong statistical relationship between macrolide use and MRSA prevalence. Use of (i) third-generation cephalosporins, (ii) all antimicrobial agents, and (iii) all antimicrobial agents except glycopeptides was also associated with MRSA prevalence. Up to 146 hospitals provided data on MRSA prevalence and key infection control parameters. Adjusted linear regression modelling provided strong evidence that infection control policy recommendations associated with lower MRSA prevalence rates were (i) use of alcohol-based solutions for hand hygiene (mean difference 10.3%, 99% CI 1.2-10.3), and (ii) placement of MRSA patients in single rooms (mean difference 11.2%, 99% CI 1.4-20.9). Hospitals with problems in implementing isolation policies had higher resistance levels (mean difference 12%, 99% CI 3.8-20.1). Additional recommendations showed less evidence of association with a low MRSA prevalence. Overall, this study highlighted significant associations between MRSA prevalence, antimicrobial use and various key infection control parameters, all of which showed significant individual variations according to geographical region.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391381     DOI: 10.1111/j.1469-0691.2006.01592.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  20 in total

1.  In Vitro and In Vivo Activities of a Bi-Aryl Oxazolidinone, RBx 11760, against Gram-Positive Bacteria.

Authors:  Tarani Kanta Barman; Manoj Kumar; Tarun Mathur; Tridib Chaira; G Ramkumar; Vandana Kalia; Madhvi Rao; Manisha Pandya; Ajay Singh Yadav; Biswajit Das; Dilip J Upadhyay; Rituraj Konwar; V Samuel Raj; Harpal Singh
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

2.  Methicillin-resistant Staphylococcus aureus (MRSA) in Europe: which infection control measures are taken?

Authors:  S Hansen; F Schwab; A Asensio; H Carsauw; P Heczko; I Klavs; O Lyytikäinen; M Palomar; I Riesenfeld-Orn; A Savey; E Szilagyi; R Valinteliene; J Fabry; P Gastmeier
Journal:  Infection       Date:  2010-03-16       Impact factor: 3.553

3.  [Multidrug resistant bacteria in the intensive care unit : Reasonable measures for prevention].

Authors:  R Fussen; S Lemmen
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-10-20       Impact factor: 0.840

4.  Antibiotics: MRSA prevention measures in German hospitals: results of a survey among hospitals, performed as part of the MRSA-KISS module.

Authors:  Iris F Chaberny; Anne Wriggers; Michael Behnke; Petra Gastmeier
Journal:  Dtsch Arztebl Int       Date:  2010-09-17       Impact factor: 5.594

5.  Emergence of MRSA in positive blood cultures from patients with febrile neutropenia--a cause for concern.

Authors:  Patrick G Morris; Tidi Hassan; Mairead McNamara; Astrid Hassan; Rebecca Wiig; Liam Grogan; Oscar S Breathnach; Edmond Smyth; Hilary Humphreys
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

6.  Detection of new mutations conferring resistance to linezolid in glycopeptide-intermediate susceptibility Staphylococcus hominis subspecies hominis circulating in an intensive care unit.

Authors:  A Sorlozano; J Gutierrez; T Martinez; M E Yuste; J A Perez-Lopez; A Vindel; J Guillen; T Boquete
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-10-30       Impact factor: 3.267

Review 7.  [Prevention of transmission of multidrug-resistant bacteria].

Authors:  R Fussen; S Lemmen
Journal:  Internist (Berl)       Date:  2015-11       Impact factor: 0.743

Review 8.  [Nosocomial infections: MRSA und CDAD as a challenge].

Authors:  W V Kern; M Dettenkofer
Journal:  Internist (Berl)       Date:  2009-06       Impact factor: 0.743

9.  Risk factors for development of aminoglycoside resistance among gram-negative rods.

Authors:  Stefan E Richter; Loren Miller; Jack Needleman; Daniel Z Uslan; Douglas Bell; Karol Watson; Romney Humphries; James A McKinnell
Journal:  Am J Health Syst Pharm       Date:  2019-10-30       Impact factor: 2.637

10.  Impact of national policies on the microbial aetiology of surgical site infections in acute NHS hospitals in England: analysis of trends between 2000 and 2013 using multi-centre prospective cohort data.

Authors:  S Elgohari; J Wilson; A Saei; E A Sheridan; T Lamagni
Journal:  Epidemiol Infect       Date:  2016-12-28       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.